The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 President’s Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
    • Media
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 President’s Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
    • Media
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
    • Media
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
      • Summit Sponsors
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Master Class 5.0 Trial Academy 2021
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

FDA Asks Leukemia Drug Maker to Suspend Marketing, Sales over Blood Clot Dangers

Posted on November 4, 2013 by Andrew Findley

News Inferno; November 1, 2013

The U.S. Food and Drug Administration (FDA) just issued an updated Drug Safety Communication asking Ariad Pharmaceuticals, the maker of the leukemia drug, Iclusig (ponatinib), to suspend its marketing and sales following increased reports of serious blood clots in arteries and veins. Iclusig received FDA approval in December 2012.

The October 31, 2013 Communication is a follow-up to its prior announcement dated October 11, 2013.

The agency indicated that it would continue to evaluate Iclusig to better understand its risks-benefit profile, and advises patients currently being treated with Iclusig to speak to their heath care professionals concerning continuing treatment. Ariad Pharmaceuticals indicated that it agreed with the agency’s request.

To read the complete article, please click here: http://www.newsinferno.com/fda-asks-leukemia-drug-maker-to-suspend-marketing-sales-over-blood-clot-dangers/

Posted in Blog, Newsletter

Comments are closed.

Recent Posts

Boy Scouts of America and The Hartford Enter $650 Million Settlement for Sex Abuse Claims

Boy Scouts of America and The Hartford Enter $650 Million Settlement for Sex Abuse Claims

April 19th, 2021

After years of legal dispute, The Hartford has entered into a settlement agreement and release with the Boy Scouts [Read More...]
Playland Operator Reaches $12 Million Bankruptcy Settlement

Playland Operator Reaches $12 Million Bankruptcy Settlement

April 19th, 2021

The Westchester County Board of Legislators last week approved a bankruptcy court settlement with Standard Amusements regardi[Read More...]
Santa Fe Agrees To a $36M Settlement With the Firms Responsible For Constructing Its Water Project

Santa Fe Agrees To a $36M Settlement With the Firms Responsible For Constructing Its Water Project

April 9th, 2021

The board of the Santa Fe city and county’s joint Buckman Direct Diversion agreed to a $36 million settlement last wee[Read More...]
Health Net Repaid $97.2M To Settle an Investigation Confirming It Over-Billed the U.S. For Veterans Care

Health Net Repaid $97.2M To Settle an Investigation Confirming It Over-Billed the U.S. For Veterans Care

April 7th, 2021

A Rancho Cordova health insurance company has repaid $97.2 million to settle an investigation into inflated claims submitted [Read More...]
Sessions at the 2021 Trial Lawyers Summit

Sessions at the 2021 Trial Lawyers Summit

April 5th, 2021

On May 4 - 7, 2021, The National Trial Lawyers will present the 10th annual Trial Lawyers Summit, hosted at the Loews Mi[Read More...]

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.